ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

 
• By Alaric DeArment

The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.

heart failure illustration
scPharmaceuticals announced data from its FREEDOM-HF study of Furoscix, which it plans to resubmit to the FDA in Q4 • Source: Shutterstock

More from Strategy

More from Business